Posted On: 02/21/2016 6:34:28 AM
Post# of 30066
Re-listened to the Avant NobleCon12 Presentation from January 19, 2016
Avant was trading at .20 and now has doubled @ .42 with a mc of $36M
- Another acquisition of IP (Parkinsons)
- Bring in house all research and development (in the works right now, but can't disclose details)
- 5-6 Test in the Pipeline
- Roche CA-125 S/S 50% & 60%
- Avant OvaDx S/S 93% & 99%
- Roche $2B in Sales from CA-125
- State of the Art Microarray platform will be used on the other diagnostic tests
- MSPrecise and OvaDX validation study is a 6 month time horizon
- OvaDX just started validation
- MSPrecise is already in validation
- Lympro is ready to start validation
- OvaDX 12 months to finish 510K - Q3 2017; FDA Approval Q4 2017
- Within 6-12 months turn Avant into a full service, R&D, commercialization diagnostic company
- 6-12 months possibly uplist to a different exchange
- Talked to Roche already about OvaDx
Avant was trading at .20 and now has doubled @ .42 with a mc of $36M
- Another acquisition of IP (Parkinsons)
- Bring in house all research and development (in the works right now, but can't disclose details)
- 5-6 Test in the Pipeline
- Roche CA-125 S/S 50% & 60%
- Avant OvaDx S/S 93% & 99%
- Roche $2B in Sales from CA-125
- State of the Art Microarray platform will be used on the other diagnostic tests
- MSPrecise and OvaDX validation study is a 6 month time horizon
- OvaDX just started validation
- MSPrecise is already in validation
- Lympro is ready to start validation
- OvaDX 12 months to finish 510K - Q3 2017; FDA Approval Q4 2017
- Within 6-12 months turn Avant into a full service, R&D, commercialization diagnostic company
- 6-12 months possibly uplist to a different exchange
- Talked to Roche already about OvaDx
(10)
(0)
